Today's headline articles

Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro - inverso cyclotetrapeptide mimetics.

Today's journal articles

Anti - invasive and anti - angiogenic activities of naturally occurring dibenzodiazepine BU - 4664L and its derivatives.

New troglitazone derivatives devoid of PPARgamma agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.

A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer.

CD147/basigin promotes progression of malignant melanoma and other cancers.

Immunomodulatory effects of radiofrequency ablation in a breast cancer model.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI

AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer (AVAXEL)

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

A Trial of Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type Non-Small-Cell Lung Cancer

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Previous Journal Entries

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

Synthesis, in vitro structure - activity relationship, and in vivo studies of 2 - arylthiazolidine - 4 - carboxylic acid amides as anticancer agents.

2,4 - Diamino - 5 - methyl - 6 - substituted arylthio - furo[2,3 - d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.

Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis.

Design, synthesis and biological evaluation of new 2,3 - diarylquinoline derivatives as selective cyclooxygenase - 2 inhibitors.

Secreted Frizzled-Related Protein 4. An Angiogenesis Inhibitor.

Design, synthesis and biological evaluation of chrysin long - chain derivatives as potential anticancer agents.

Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100.

New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase III study (NCT00102804).

Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype.

Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.

Discovery of matrix metalloproteases selective and activated peptide - doxorubicin prodrugs as anti - tumor agents.

Orally administered Endoxifen is a new therapeutic agent for breast cancer.

Synthesis and Biological Evaluation of Triazol - 4 - ylphenyl - Bearing Histone Deacetylase Inhibitors as Anticancer Agents.

Novel amidino substituted 2 - phenylbenzothiazoles: Synthesis, antitumor evaluation in vitro and acute toxicity testing in vivo.

Diallyl trisulphide-induced apoptosis in human melanoma cells involves downregulation of Bcl-2 and Bcl-xL expression and activation of caspases.

Rho kinase inhibitor Y-27632 facilitates recovery from experimental peripheral neuropathy induced by anti-cancer drug cisplatin.

Delivery of paclitaxel by physically loading onto poly(ethylene glycol) (PEG)-graft-carbon nanotubes for potent cancer therapeutics.

Today's News Items

Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Melanoma

Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval

Training Courses & Meetings

No events listed

Previous News Items

ArQule Announces Initiation of Clinical Programs with ARQ 197 in Germ Cell Tumors and Colorectal Cancer

Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma

LEO Pharma’s PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition

Herceptin now approved in the EU for patients with HER2-positive advanced stomach cancer

GSK’s TYKERB® receives accelerated approval for first-line combination treatment of hormone receptor positive, HER2+/ErbB2+ metastatic breast cancer

Teva Announces FDA Accepts BLA for XM02

Onyx Pharmaceuticals Announces Agreement with the FDA on a Special Protocol Assessment for Planned Phase 3 Carfilzomib Combination Trial in Relapsed Multiple Myeloma

---

For faster discovery, automatically organize PubMed results into categories